Your browser doesn't support javascript.
loading
Histone deacetylase 6 as a novel promising target to treat cardiovascular disease.
Wu, Ya-Xi; Li, Bing-Qian; Yu, Xiao-Qian; Liu, Yu-Lin; Chui, Rui-Hao; Sun, Kai; Geng, Dian-Guang; Ma, Li-Ying.
Affiliation
  • Wu YX; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
  • Li BQ; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
  • Yu XQ; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
  • Liu YL; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
  • Chui RH; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
  • Sun K; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
  • Geng DG; Key Laboratory of Cardio-Cerebrovascular Drugs' China Meheco Topfond Pharmaceutical Co. Zhumadian Henan China.
  • Ma LY; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
Cancer Innov ; 3(3): e114, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38947757
ABSTRACT
Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancer Innov Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancer Innov Year: 2024 Document type: Article Country of publication: